AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2480613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (400, 800, or 1200 mg daily for 6 weeks)
Number of subjects: 24
Study 30537561 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 JAU
Number of subjects: 1042
Study 30537561 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 JAU
Number of subjects: 1042
Study 30537561 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 JAU
Number of subjects: 1042
Study 30537561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1042
Study 28699556 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-designed interventions for dengue prevention, specific actions not detailed, duration not available.
Number of subjects: 0
Study 28699556 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-led trials with participatory research protocol, specific actions not detailed, duration not available.
Number of subjects: 0
Study 28699556 — intervention group
Group type: EXPERIMENTAL
Intervention: Community involvement in dengue control activities, specific actions not detailed, duration not available.
Number of subjects: 0
Study 23828912 — intervention group
Group type: EXPERIMENTAL
Intervention: HPS school
Number of subjects: 3
Study 23828912 — intervention group
Group type: EXPERIMENTAL
Intervention: HE school
Number of subjects: 3
Study 23828912 — intervention group
Group type: COMPARATOR
Intervention: Control school
Number of subjects: 3
Study 23562431 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 2528
Study 23562431 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 2528
Study 23562431 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 2528
Study 21982141 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation training (28 weeks)
Number of subjects: 30
Study 21982141 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 19375570 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 82
Study 19375570 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 82
Study 17472818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive-dose statin therapy (atorvastatin or simvastatin 80 mg)
Number of subjects: 27548
Study 15107158 — intervention group
Group type: EXPERIMENTAL
Intervention: Smiling faces (positively perceived novel faces)
Number of subjects: 0
Study 15107158 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal association with positive affect (positively valenced prime)
Number of subjects: 0
Study 15107158 — intervention group
Group type: COMPARATOR
Intervention: Participants in happy mood states
Number of subjects: 0
Study 11134500 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyl-L-tyrosine (graded levels)
Number of subjects: 13
Study 11134500 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 13
Study 8956926 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training with feedback trials and transfer trials
Number of subjects: 12
Study 8956926 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training
Number of subjects: 12
Study 2123946 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 24
Study 2123946 — intervention group
Group type: COMPARATOR
Intervention: Polymyxin B
Number of subjects: 24
Study 6991102 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MeCCNU, chlorpromazine (50 mg/m2 im), and caffeine (600 mg/m2 sc)
Number of subjects: 157
Study 6991102 — intervention group
Group type: COMPARATOR
Intervention: Methyl‐CCNU (MeCCNU) (200 mg/m2 orally every 6 weeks)
Number of subjects: 157
Study 6991102 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 157
Study 31257430 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin coconut oil application (Group A)
Number of subjects: 2294
Study 31257430 — intervention group
Group type: COMPARATOR
Intervention: Body massage without any application (Group B)
Number of subjects: 2294
Study 30641346 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS (2400 pulses/session)
Number of subjects: 44
Study 30641346 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS (2400 pulses/session)
Number of subjects: 44
Study 28616929 — intervention group
Group type: EXPERIMENTAL
Intervention: He‐Ne laser therapy
Number of subjects: 40
Study 28616929 — intervention group
Group type: COMPARATOR
Intervention: Control (no He‐Ne laser therapy)
Number of subjects: 40
Study 25592805 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine extended release (XR)
Number of subjects: 66
Study 25592805 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine immediate release (IR)
Number of subjects: 66
Study 24685117 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic reminder activated in the patient's electronic medical record during a synchronous medical appointment throughout the year of intervention
Number of subjects: 0
Study 24685117 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electronic reminder)
Number of subjects: 0
Study 22011946 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically supervised weight management (MSWM) program with monthly visits over 6 months
Number of subjects: 55
Study 22011946 — intervention group
Group type: COMPARATOR
Intervention: Usual care for 6 months
Number of subjects: 55
Study 22011946 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically supervised weight management (MSWM) program
Number of subjects: 55
Study 20701962 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 202
Study 20701962 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 202
Study 20701962 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Vertebroplasty and Conservative treatment
Number of subjects: 202
Study 18614861 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/r 800/100 mg qd
Number of subjects: 689
Study 18614861 — intervention group
Group type: COMPARATOR
Intervention: LPV/r 800/200 mg total daily dose
Number of subjects: 689
Study 18614861 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/r in patients with HIV-1 RNA ≥ 100,000 copies/ml
Number of subjects: 689
Study 18614861 — intervention group
Group type: COMPARATOR
Intervention: LPV/r in patients with HIV-1 RNA ≥ 100,000 copies/ml
Number of subjects: 689
Study 15747448 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 micrograms/day
Number of subjects: 1637
Study 15747448 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 40 micrograms/day
Number of subjects: 1637
Study 15747448 — intervention group
Group type: COMPARATOR
Intervention: Alendronic acid
Number of subjects: 1637
Study 11834100 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric loading with detaching hooks (105% of concentric 1RM for lowering, 100% for raising)
Number of subjects: 8
Study 10520081 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ET-1 (nebulized dose range 0.96-15.36 nmol)
Number of subjects: 10
Study 10520081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8774159 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of high molecular weight hyaluronan
Number of subjects: 240
Study 8774159 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 240
Study 1730816 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (400 mg/day, intravaginally)
Number of subjects: 6
Study 1730816 — intervention group
Group type: COMPARATOR
Intervention: GnRH (10 microgram/pulse every 90 min)
Number of subjects: 6
Study 1730816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6377712 — intervention group
Group type: EXPERIMENTAL
Intervention: co‐tetroxazine (100 mg tetroxoprim and 250 mg sulphadiazine) b.i.d.
Number of subjects: 127
Study 6377712 — intervention group
Group type: COMPARATOR
Intervention: co‐trimoxazole (160 mg trimethoprim and 800 mg sulphamethoxazole) b.i.d.
Number of subjects: 127
Study 30624198 — intervention group
Group type: EXPERIMENTAL
Intervention: Education only
Number of subjects: 150
Study 30624198 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus pharmacist consultation
Number of subjects: 150
Study 30624198 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 150
Study 29188338 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (PG 2.8 ± 0.2 mmol/l, approximate duration 55 min)
Number of subjects: 26
Study 29188338 — intervention group
Group type: COMPARATOR
Intervention: Euglycaemia (PG 5.5 mmol/l ± 10%)
Number of subjects: 26
Study 29188338 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (PG 2.8 ± 0.2 mmol/l)
Number of subjects: 26
Study 26325537 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume plasma exchange (HVP) for three days
Number of subjects: 182
Study 26325537 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (SMT)
Number of subjects: 182
Study 26325537 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume plasma exchange (HVP) prior to transplantation
Number of subjects: 182
Study 26325537 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume plasma exchange (HVP)
Number of subjects: 182
Study 25475465 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 207566
Study 22840725 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery without stirrups
Number of subjects: 214
Study 22840725 — intervention group
Group type: COMPARATOR
Intervention: Delivery in stirrups
Number of subjects: 214
Study 19644125 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for simple target phonemes
Number of subjects: 6
Study 19644125 — intervention group
Group type: COMPARATOR
Intervention: Treatment for complex targets
Number of subjects: 6
Study 16329785 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day burnout intervention program
Number of subjects: 59
Study 12150629 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy and adenoidectomy (T&A)
Number of subjects: 41
Study 9785144 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg per day (initially 2.5 to 5 mg, increased to 10 mg in five patients)
Number of subjects: 9
Study 9785144 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 9
Study 7884424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural cisplatin (IPL CDDP)
Number of subjects: 11
Study 7884424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin (IP CDDP)
Number of subjects: 11
Study 7884424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary cisplatin (IC CDDP)
Number of subjects: 11
Study 2346543 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 mg acetylsalicylic acid (ASA) daily
Number of subjects: 12
Study 2346543 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 mg paracetamol daily
Number of subjects: 12
Study 2346543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 380725 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocryptine
Number of subjects: 51
Study 380725 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 30282645 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS Health Check attendance
Number of subjects: 138788
Study 30282645 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS Health Check attendees
Number of subjects: 138788
Study 30282645 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS Health Check attendees in deprived areas
Number of subjects: 138788
Study 30282645 — intervention group
Group type: COMPARATOR
Intervention: Non-attendees
Number of subjects: 138788
Study 28121498 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab (10 mg/kg)
Number of subjects: 2655
Study 28121498 — intervention group
Group type: EXPERIMENTAL
Intervention: Actoxumab plus bezlotoxumab (10 mg/kg each)
Number of subjects: 2655
Study 28121498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2655
Study 25746086 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-needling
Number of subjects: 67
Study 23506972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary darbepoetin‐α (ARANESP®; Jeil‐Kirin Pharm., Korea) 300μg
Number of subjects: 80
Study 23506972 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 80
Study 21775528 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index diet (LGI; GI: 79)
Number of subjects: 29
Study 21775528 — intervention group
Group type: COMPARATOR
Intervention: High Glycemic Index diet (HGI; GI: 103)
Number of subjects: 29
Study 20054092 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailing of the trial information sheet separate from the screening invitation
Number of subjects: 0
Study 20054092 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension of recruitment to mobile screening units in Nottingham
Number of subjects: 0
Study 20054092 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of an additional member of staff
Number of subjects: 0
Study 20054092 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplification of the trial information sheet
Number of subjects: 0
Study 20054092 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall acceptance rate of trial participation
Number of subjects: 0
Study 20054092 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recruitment rate over time
Number of subjects: 0
Study 17122577 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.5 MAC
Number of subjects: 15
Study 17122577 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.0 MAC
Number of subjects: 15
Study 17122577 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.5 MAC
Number of subjects: 15
Study 14710137 — intervention group
Group type: EXPERIMENTAL
Intervention: Support by untrained lay women starting in early labor and continuing into the postpartum period
Number of subjects: 8
Study 14710137 — intervention group
Group type: COMPARATOR
Intervention: Trained lay women, female relatives, nurses, lay midwives, and student lay midwives
Number of subjects: 8
Study 11723269 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 2 mg
Number of subjects: 903
Study 11723269 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 6.25 mg
Number of subjects: 903
Study 11723269 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 903
Study 11723269 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 25 mg
Number of subjects: 903
Study 11723269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 903
Study 9038425 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine therapy
Number of subjects: 163
Study 9038425 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline total BOD value
Number of subjects: 163
Study 9038425 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent changes in BOD from baseline to exit
Number of subjects: 163
Study 8188893 — intervention group
Group type: COMPARATOR
Intervention: Liquid nitrogen cryotherapy
Number of subjects: 13
Study 8188893 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser therapy
Number of subjects: 13
Study 8188893 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser therapy
Number of subjects: 13
Study 2959882 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol
Number of subjects: 0
Study 2959882 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 0
Study 2959882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29685777 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.3% drops
Number of subjects: 112
Study 29685777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 27450973 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia (MTH) in normokalemia patients
Number of subjects: 135
Study 27450973 — intervention group
Group type: COMPARATOR
Intervention: Fever control in normokalemia patients
Number of subjects: 135
Study 27450973 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia (MTH) in hypokalemia patients
Number of subjects: 135
Study 27450973 — intervention group
Group type: COMPARATOR
Intervention: Fever control in hypokalemia patients
Number of subjects: 135
Study 25124186 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting (PCI)
Number of subjects: 4566
Study 25124186 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 4566
Study 22755547 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient/therapist feedback and clinical decision-support tools
Number of subjects: 370
Study 22755547 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 370
Study 20629698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannula valve connector
Number of subjects: 290
Study 20629698 — intervention group
Group type: COMPARATOR
Intervention: No cannula valve connector
Number of subjects: 290
Study 18714934 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix allograft
Number of subjects: 7
Study 18714934 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft with coronally positioned flap
Number of subjects: 7
Study 15823228 — intervention group
Group type: EXPERIMENTAL
Intervention: quarter-laser zona thinning assisted hatching (qLZT-AH)
Number of subjects: 150
Study 15823228 — intervention group
Group type: COMPARATOR
Intervention: Control group (no qLZT-AH)
Number of subjects: 150
Study 12208708 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 25
Study 12208708 — intervention group
Group type: EXPERIMENTAL
Intervention: Artisan phakic intraocular lens (PIOL)
Number of subjects: 25
Study 10604044 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine combination therapy (azelastine nasal spray 0.14 mg twice daily + azelastine tablet 2 mg at night)
Number of subjects: 300
Study 10604044 — intervention group
Group type: COMPARATOR
Intervention: Azelastine nasal spray only (after day five)
Number of subjects: 300
Study 10604044 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet with nasal spray (control group)
Number of subjects: 300
Study 7723663 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment for 2 years (Group 1)
Number of subjects: 12
Study 7723663 — intervention group
Group type: COMPARATOR
Intervention: Testosterone treatment for 1 year followed by 1 year without treatment (Group 2)
Number of subjects: 12
Study 7723663 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (both groups)
Number of subjects: 12
Study 1975162 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 50 micrograms twice a day
Number of subjects: 12
Study 1975162 — intervention group
Group type: COMPARATOR
Intervention: Inhaled salbutamol 200 micrograms four times a day
Number of subjects: 12
Study 18492 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg triazolam
Number of subjects: 118
Study 18492 — intervention group
Group type: COMPARATOR
Intervention: 30 mg flurazepam
Number of subjects: 118
Study 31562569 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education for 1 year
Number of subjects: 1564
Study 31088887 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 26
Study 31088887 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 26
Study 28489877 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention, including at least 1 hour/day of moderate PA and additional strenuous weekly activity, collective walks, and theoretical group sessions.
Number of subjects: 210
Study 28489877 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PA intervention).
Number of subjects: 210
Study 28489877 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of PA intervention vs control.
Number of subjects: 210
Study 25616944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided inguinal field block (n = 42)
Number of subjects: 86
Study 25616944 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia block (n = 44)
Number of subjects: 86
Study 23347259 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-carried ultrasound (HCU) examination by briefly trained medical students
Number of subjects: 45
Study 23347259 — intervention group
Group type: COMPARATOR
Intervention: Auscultation-based physical examination
Number of subjects: 45
Study 23347259 — intervention group
Group type: COMPARATOR
Intervention: Standard echocardiography study
Number of subjects: 45
Study 21622774 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase
Number of subjects: 212
Study 21622774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 18799509 — intervention group
Group type: EXPERIMENTAL
Intervention: Sniff nasal inspiratory pressure
Number of subjects: 113
Study 18799509 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis (CF)
Number of subjects: 113
Study 18799509 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular disease (NM)
Number of subjects: 113
Study 18799509 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic scoliosis
Number of subjects: 113
Study 18799509 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal value of sniff nasal pressure
Number of subjects: 113
Study 18799509 — intervention group
Group type: EXPERIMENTAL
Intervention: Low value of sniff nasal pressure
Number of subjects: 113
Study 16923414 — intervention group
Group type: EXPERIMENTAL
Intervention: TandemHeart percutaneous ventricular assist device (pVAD)
Number of subjects: 42
Study 16923414 — intervention group
Group type: COMPARATOR
Intervention: Intraaortic balloon pumping (IABP)
Number of subjects: 42
Study 15191618 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐Acetyl Aspartate (NAA/Cr ratio) levels in normal appearing white matter
Number of subjects: 31
Study 15191618 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Functional Composite score
Number of subjects: 31
Study 15191618 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological Rating Scale
Number of subjects: 31
Study 15191618 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulation Index scale
Number of subjects: 31